Aspire-Lakewood Holdings, Inc.
ASBP · XNASCIK 1847345fmd_0XAK6DDEZ084VQE61250WH0H92Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Apr 01, 2021 to Jun 30, 2026, 20 periods
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Total revenues | – | – | – | 0 |
| Cost of revenue | – | – | – | 0 |
| Gross profit | – | – | – | (0) |
| Research and development | – | – | 0 | 1 |
| Selling, general and administrative | – | – | 1 | 18 |
| Total operating expenses | 1 | 1 | 1 | 19 |
| Operating income | – | – | (1) | (19) |
| Interest expense | – | 0 | 0 | 9 |
| Interest and investment income | 4 | 6 | 1 | – |
| Other non-operating income (expense) | 4 | 6 | (0) | (5) |
| Income before taxes | – | – | (1) | (24) |
| Income tax expense | – | – | 0 | – |
| Net income from continuing operations | – | – | (1) | – |
| Net income | 3 | 4 | (1) | (24) |